In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.

Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study / F. Bartoli, D. Cavaleri, T. Callovini, I. Riboldi, C. Crocamo, A. D(')Agostino, G. Martinotti, F. Bertolini, G. Ostuzzi, C. Barbui, G. Carr(`a), F. Boschello, C. Gastaldon, M.A. Mazzi, M. Nos('e), D. Papola, G. Perini, A. Piccoli, M. Pievani, M. Purgato, M. Ruggeri, F. Tedeschi, S. Terlizzi, G. Turrini, M. Caroleo, P. De Fazio, F. Magliocco, G. Raffaele, M. Chirico, F. Ferrato, I. Limosani, D. Mastromo, E. Monzani, E.G. Ostinelli, M. Porcellana, F. Restaino, P.M. Annese, S. Bolognesi, M. Cerretini, A. De Capua, S. Debolini, M. Del Zanna, F. Fargnoli, A. Giannini, L. Luccarelli, C. Lucii, E. Pierantozzi, F. Tozzi, F. Bardicchia, G. Cardamone, E. Facchi, N. Magnani, F. Soscia, B. Biancosino, S. Zotos, M. Giacomin, F. Pompei, M. Spano, F. Zonta, A. Buzzi, C. Callegari, R. Calzolari, I. Caselli, M. Diurni, E.L. Giana, M. Ielmini, A. Milano, N. Poloni, E. Sani, D. Zizolfi, G. Alberini, P. Bortolaso, S. Cazzamalli, C. Costantini, A. Di Caro, C. Paronelli, S. Piantanida, M. Piccinelli, P. Alessandro, S.V. Barbanti, C. D(')Ippolito, M. Gozzi, V. Moretti, M. Corbo, L. Di Capro, M. di Giannantonio, F. Fiori, M. Lorusso, V. Mancini, D. Viceconte, C. Calandra, M. Luca, M.S. Signorelli, F. Suraniti, B. Balzarro, G. Boncompagni, V. Caretto, R. Emiliani, P. Lupoli, M. Menchetti, E. Rossi, V. Storbini, I. Tarricone, L. Terzi, M. Boso, C. Catania, G. De Paoli, P. Risaro, F. Aspesi, M. Bava, A. Bono, G. Brambilla, G. Castagna, S. Lucchi, R. Nava, M. Provenzi, T. Tabacchi, M. Tremolada, E. Verrengia, M. Barchiesi, M.G. Oriani, A. Aguglia, M. Ferro, L. Ghio, R. Beneduce, L. Laffranchini, L.R. Magni, G. Rossi, G.B. Tura, L. Addeo, G. Balletta, E. De Vivo, R. Di Benedetto, V.F. Parise, B. Carpiniello, F. Pinna, D. Pecile, C. Mattei, T. Bonavigo, E.P. Fabrici, S. Panarello, G. Peresson, C. Vitucci, M. Pacetti, F. Gardellin, S. Strizzolo, E. Cossetta, C. Fizzotti, D. Moretti, L. Di Gregorio, F. Sozzi, G. Colli, D. La Barbera, S. Laurenzi. - In: PSYCHIATRY RESEARCH. - ISSN 0165-1781. - 309:(2022 Mar), pp. 114405.1-114405.4. [10.1016/j.psychres.2022.114405]

Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study

A. D(')Agostino;M. Chirico;I. Limosani;E.G. Ostinelli;M. Porcellana;
2022

Abstract

In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.
Aripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate 1-month
Settore MED/25 - Psichiatria
Article (author)
File in questo prodotto:
File Dimensione Formato  
Bartoli et al. - 2022 - Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohyd.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 577.28 kB
Formato Adobe PDF
577.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/934398
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact